
Resistant and Refractory Hypertension: A Guideline Topline for Primary Care
Hypertension that is resistant or refractory to treatment increases the risk of comorbidity and cardiovascular risk. Click through this at-a-glance review of key issues.
This Patient Care Guideline Topline on resistant and refractory hypertension is drawn from a 2023 review, in a series on controversies in hypertension published this year in The American Journal of Medicine.1 The last clinical practice guideline on hypertension in the US was issued by the American Academy of Family Physicians (AAFP)2 in 2022, and was highlighted in a Guideline Topline
References
1. Filippone EJ, Naccarelli GV, Foy AJ. Controversies in hypertension V: Resistant and refractory hypertension. Am J Med. 2024; 137:12-22. doi: 10.1016/j.amjmed.2023.09.015
2. Coles S, Fisher L, Lin KW, et al. Blood pressure targets in adults with hypertension: A clinical practice guideline from the AAFP. Am Fam Physician. 2022 Dec;106(6):online
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

































































































































































































































































































